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Human enterovirus 71 (EV71) epidemics have affected various countries in the past 40 years. EV71 commonly
causes hand, foot and mouth disease (HFMD) in children, but can result in neurological and cardio-
respiratory complications in severe cases. Genotypic changes of EV71 have been observed in different places
over time, with the emergence of novel genotypes or subgenotypes giving rise to serious outbreaks. Since
the late 1990s, intra- and inter-typic recombination events in EV71 have been increasingly reported in the
Asia-Pacific region. In particular, ‘double-recombinant’ EV71 strains belonging to a novel genotype D have
been predominant in mainland China and Hong Kong over the last decade, though co-circulating with a
minority of other EV71 subgenotypes and coxsackie A viruses. Continuous surveillance and genome studies
are important to detect potential novel mutants or recombinants in the near future. Rapid and sensitive
molecular detection of EV71 is of paramount importance in anticipating and combating EV71 outbreaks.
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H
uman enterovirus 71 (EV71) is a small, non-
enveloped, icosahedral virus that belongs to the
human EV species A in the genus Enterovirus
within the family Picornaviridae. EV71 and coxsackie-
virus A16 (CVA16) are common etiological agents of
hand, foot and mouth disease (HFMD) in children, but
the former can cause severe complications, such as aseptic
meningitis, acute flaccid paralysis (AFP), meningoence-
phalitis and cerebellitis, with mortality rate ranging from
10 to 25.7% (1, 2). Another neurotropic EV, poliovirus,
is nearly completely eradicated as a result of global
immunization efforts (3). Thus, in the absence of effective
vaccines and antivirals against EV71, EV71 may become
an important pathogen, replacing poliovirus, with in-
creasing health threat to humans. Since the late 1990s,
EV71 has seriously affected the Asia-Pacific region
(410). In recent years, there have been an increasing
number of reports of HFMD outbreaks with fatal cases
due to EV71 in China (1118). In 2012, EV71 was found
to be associated with ‘mystery disease’ that killed most
patients shortly after admission to hospital in Cambodia
(19). EV71 is well known to cause outbreaks, which often
occur in a cyclical pattern, every 23 years, in various
countries (20).
The single-stranded positive-sense RNA genome of
EV71 is around 7.4-kb long, which is flanked by 5? and 3?
untranslated regions (UTRs). The polyprotein consists
of P1, P2, and P3 regions, which encodes structural
proteins, VP4, VP2, VP3, VP1, and non-structural pro-
teins, 2A, 2B, 2C and 3A, 3B, 3C, 3D, respectively. Based
on molecular typing using VP4 and VP1 gene sequences
(21), EV71 is classified into three genotypes, A, B
(subgenotypes B1B5), and C (subgenotypes C1C5)
(21, 22). A separate subgenotype B0 has recently been
identified in a retrospective analysis of EV71 strains in
the Netherlands from 1963 to 1967 (23). Two studies on
complete genome analysis of EV71 strains of subgeno-
type C4 suggested that this subgenotype should be
classified as a novel genotype D (24, 25).
Mutation and recombination are well-known pheno-
mena in EV evolution. The infidelity of EV 3D poly-
merase leads to their mutation rates of around one per
genome per replication (26). Mutations in various regions
such as 5?UTR, VP1, VP2, 2A, 2C, and 3D of EV71 have
(page number not for citation purpose)
REVIEW ARTICLE
Emerg Health Threats J 2013.# 2013 Cyril C. Y. Yip et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0
Unported (CC BY 3.0) License and the url http://creativecommons.org/licenses/by/3.0/, permitting all non-commercial use, distribution, and reproduction in
any medium, provided the original work is properly cited.
1
Citation: Emerg Health Threats J 2013, 6: 19780 - http://dx.doi.org/10.3402/ehtj.v6i0.19780
shown to be associated with alterations of virulence in
animal models and humans (2733). Recombination
occurs in enteroviruses as a result of template switching
during negative-strand synthesis, which is thought to
be mediated by a ‘copy-choice’ mechanism (34, 35).
Inter-typic and intra-typic recombination events were
frequently detected in EV71 strains circulating in the
Asia-Pacific region (24, 3638). In recent years, recurring
HFMD outbreaks caused by EV71 of subgenotype C4
(‘double-recombinant’ belonging to a novel genotype D)
have been reported in Hong Kong and different provinces
in China (1116, 39). In this review, we provide an update
on the epidemiology and genetic evolution of EV71.
Methods
Keywords including ‘EV71’, ‘EV71’, ‘EV’, ‘epidemiology’,
‘evolution’, ‘genotype’, ‘mutation’, and ‘recombination’
were used for Medline search. The search results were then
manually screened for literature on the epidemiology and
genetic evolution of EV71.
Epidemiology of EV71
Many studies have reported the detection of EV71 in
clinical specimens of patients from various countries in
Asia, Australia, Europe, and America (Table 1) (4047).
During 19691972, the prototype EV71 strain BrCr and
related strains were first identified from patients with
neurological disease in California (40). In the early 1970s,
EV71 occurred in patients mainly with meningitis in
USA, Sweden, and Australia (4143). A large outbreak of
poliomyelitis-like disease occurred in Bulgaria in 1975,
during which 21% of around 700 cases showed paralytic
forms and 27 were fatal as a result of EV71 infections (44,
48, 49). Three years later, EV71 was the major causative
agent of meningitis and encephalitis during the severe
epidemic of acute central nervous system (CNS) diseases
in Hungary (45). During the 1970s, Japan experienced
two outbreaks of HFMD by EV71, in which a significant
proportion of patients with HFMD accompanied CNS
disorders and some of them died (46, 50, 51). Based on
the above findings, EV71 isolates in America, Australia,
and Europe were strongly associated with severe CNS
complications, while those in Japan showed both derma-
totropic and neurotropic features. Mortality rates due to
EV71 outbreaks in the 1980s were low when compared
to those occurred in Bulgaria and Hungary in the
1970s (52).
Since the late 1990s, recurrent EV71 epidemics of
various scales have occurred in the Asia-Pacific region,
including Australia, China, Malaysia, Singapore, Taiwan,
Thailand, and Vietnam (410). A huge number of deaths
associated with HFMD outbreaks occurred in Malaysia,
Taiwan, and China. During the outbreak with 2,628
HFMD cases in Sarawak Malaysia, 29 children died due
to rapidly progressive cardiorespiratory failure caused by
EV71 in 1997 (53). In Taiwan, 78 of 405 children with
severe complications died in the large HFMD outbreak
in 1998 (54), followed by another outbreak in 2000 with
41 deaths among 80,677 HFMD cases (8). During these
two outbreaks, EV71 accounted for a major proportion
of deaths in children in Taiwan. Since May 2008, HFMD
has been a notifiable disease in the national surveillance
system in China (17). From 2008 to 2011, recurring
HFMD outbreaks have occurred in various provinces in
China and the number of HFMD cases increased from
488,955 with 126 deaths to 1,619,706 with 509 deaths
(1118, 55). During this period, coxsackieviruses A2, A4,
A5, A6, A10, A12, A16, and EV71 were co-circulating in
the outbreaks (13, 14, 56), of which EV71 was responsible
for most fatal cases (16).
The number of EV71-associated HFMD cases was rela-
tively low in Europe compared to that in the Asia-Pacific
region. In a prospective study from Norway (57), EV71
was detected in stool specimens from asymptomatic
children, and the absence of disease may be due to host
factors (immune system, genetic effect, nutritional and
hygiene status) and/or viral factors. Since HFMD is not a
disease under surveillance in Europe and healthy indivi-
duals are usually not the subjects under surveillance, the
prevalence of EV71 may be underestimated (23, 5860).
EV71 epidemics usually occur in summer months. In
studies with clinical specimens collected throughout the
year, seasonal patterns of EV71 infection have been
demonstrated. Several studies showed that EV71 could
be detected throughout the year, but its predominance
was found in different months in various regions (9, 10,
57). A higher incidence was observed in summer months
in Norway (57), but in the fall in Vietnam and Thailand
(9, 10). Some countries have shown two peak activities of
EV71 infections during their study periods. In 1998, there
were two peaks of EV71 infections (one in June and the
other in October) in the large outbreak in Taiwan (61
63). In southern Vietnam, a smaller peak (MarchMay)
and a higher peak (SeptemberDecember) of EV71 infec-
tions were found in 2005, and these months are interim
periods between the dry and wet seasons (10). In Hong
Kong, a higher peak (MayJune) and a smaller peak
(OctoberDecember) have been noted in 2008 (39). In the
Netherlands, a higher peak (JuneJuly) and a smaller
peak (SeptemberOctober) of cases were observed during
19632008 (23). Some studies have also reported varia-
tion of peak season between different years. In Australia,
peak activity of EV71 shifted from summer in 1973 to
winter in 1986 (43, 59, 64). In Japan, EV71 was detected
in summer months in 19981999, but was only detected in
the fall during 20012002 (65). In Malaysia, EV71
predominance shifted from summer in 2000 to spring in
2003 (66). The observed seasonal changes may be due to
climatic factors that favor viral survival, variations in
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Table 1. Summary of major EV71 outbreaks in different geographical regions
Time period Country/region
No. of cases
with EV71
No. of deaths
due to EV71 Clinical findings (no. of cases) Genotype(s) References
19691972 California 20 1 Meningitis (10), encephalitis (7), meningoencephalitis (1), myocarditis
(1)
A 40, 79
1972 New York 11 0 Meningitis (9), encephalitis (1), HFMD (1) 41
19721973 Australia 49 0 Aseptic meningitis (39), rash alone (5), acute RTI (4), infective
polyneuritis (1)
43
1973 Sweden 195 0 Mainly aseptic meningitis, some with HFMD 42
1975 Bulgaria 65 (by virus isolation);
282 (by serology)
27 Aseptic meningitis (30), bulbar forms with fatal outcome (27),
poliomyelitis syndrome (8)
48
1977 New York 12 0 CNS disease (7), HFMD (4), acute RTI (1), gastroenteritis (1) 71
1978 Hungary 323 47 (not clear if all
due to EV71)
Meningitis (161), encephalitis (145), poliomyelitis (13), HFMD (4) 45
1973, 1978 Japan 71 Some died (details
not given)
Mainly HFMD, some with CNS disorders 46
1986 Australia 114 0 Rash (61), RTI (35), meningoencephalitis (34) 64
19881990 Brazil 39 0 Acute neurological disease (24) 149
1997 Malaysia 2,628 HFMD cases 29 Cardiorespiratory failure (29) 53
19971998 Singapore 39 0 Mainly HFMD, some with aseptic meningitis, AFP, myocarditis,
coxsackie-like disease and neonatal pyrexia
150
1998 Taiwan 469 34 HFMD or herpangina, 78 with severe complications (mainly
encephalitis)
54, 6163
19972000 Peninsular Malaysia 43 strains 0 HFMD (33), encephalitis (4), myocarditis (2), meningitis (1), HFMD with
meningitis (1), oral ulceration (1), paralysis (1)
B3, B4, C1, C2 6
19982000 Taiwan 340 (53 isolates for
phylogenetic study)
7 (from phylogenetic
study)
HFMD (20), HFMD with CNS involvement (12), meningoencephalitis (5),
encephalitis (4), meningitis (2), CNS symptoms (1), HFMD with acute
pharyngitis and asthmatic bronchitis (1), HFMD with acute gastritis (1),
herpangina (1)
Mainly C in
1998, B in
1999 and 2000
8
1999 Perth 14 0 Meningitis (5), acute cerebellar ataxia (2), acute transverse myelitis (2),
GuillainBarre´ syndrome (2), benign intracranial hypertension (1), febrile
convulsion (1), opso-myoclonus syndrome (1)
68
2000 Korea 12 0 HFMD (8), HFMD and encephalitis (2), HFMD and bronchiolitis (1), AFP
(1)
C 106
2000 Singapore 81 4 HFMD (76), non-HFMD [aseptic meningitis, herpangina, GuillainBarre´
syndrome] (5)
B4 7
19982003 Japan 110 strains 0 HFMD (95), URTI (4), influenza-like illness (3), herpangina (3),
exanthema (3), meningitis (2)
B4, B5, C2, C4 65
H
u
m
a
n
e
n
te
ro
viru
s
7
1
e
p
id
e
m
ic
s
C
ita
tio
n
:
E
m
e
rg
H
e
a
lth
T
h
re
a
ts
J
2
0
1
3
,
6
:
1
9
7
8
0
-
h
ttp
://d
x.d
o
i.o
rg
/1
0
.3
4
0
2
/e
h
tj.v6
i0
.1
9
7
8
0
3
(p
a
g
e
n
u
m
b
e
r
n
o
t
fo
r
c
ita
tio
n
p
u
rp
o
s
e
)
Table 1 (Continued)
Time period Country/region
No. of cases
with EV71
No. of deaths
due to EV71 Clinical findings (no. of cases) Genotype(s) References
20002003 Malaysia 277 4 Mild HFMD (187), HFMD with CNS involvement (52), severe non-CNS
HFMD (34), aseptic meningitis (4)
B4, B5, C1 66
2005 Vietnam 173 3 HFMD (173), of which 51 complicated by acute neurological disease C1, C4, mainly
C5
10
2006 Brunei 34 2 HFMD or herpangina B4, mainly B5 95
1986, 2007 The Netherlands 40 in 1986, 58 in
2007
0 Mainly fever, meningitis or encephalitis, gastrointestinal symptoms B2 in 1986,
mainly C2 in
2007
23
20062007 France 28 1 Mainly fever, some with HFMD, meningitis, acute respiratory distress
syndrome, gastroenteritis
C1 and C2 in
2006, C2 in
2007
60
2007 Germany 13 0 Meningitis (9), HFMD (1) C2 58
2007 Denmark 17 0 Meningitis (5), HFMD (4), unspecified viral infection (3), gastroenteritis
(2), viral enteritis (1), HFMD with meningitis (1), meningitis with enteritis
(1)
B5, C1, C2 59
2008 Hong Kong 98 1 HFMD (89), herpangina (2), fever, URTI, rash and pneumonia (7)
(11.2% of the cases with complications including meningitis or
encephalitis, pneumonia, AFP and shock)
B5, C2, mainly
C4
39
2008 China*Fuyang 59 6 HFMD: mild (17), severe (36), fatal (6) C4 11
2008 China *Guangdong 551 21 Complete data available for 185 cases: 95% rash; encephalitis (7),
paralysis (1), neurogenic pulmonary edema (5), pneumonia (4)
C4 12
20082009 Thailand 23 1 Mainly HFMD, brainstem encephalitis (2) B5, C1, C2,
mainly C4
9
2009 China*Beijing,
Shandong,
Guangdong
134 0 HFMD C4 13
20092010 China*Shanghai 378 Some died
(details not given)
HFMD, some with CNS involvement C4 14
2010 China*Nanchang 63 0 HFMD C4 15
20082011 China*Ningbo 1,503 10 HFMD: mild (1,349), severe (144), fatal (10) C4 16
AFPacute flaccid paralysis; CNScentral nervous system; HFMDhand, foot and mouth disease; URTIupper respiratory tract infections.
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host immune response to infection and host behaviors
that increase contact between individuals.
Clinical impact of EV71 infection
EV71 infection usually causes HFMD or herpangina
(54, 67), but it can result in more severe illness, which is
characterized by high-grade fever (body temperature
above 398C), vomiting, and cardiopulmonary or neurolo-
gical complications (54). In the large-scale EV71 epidemic
in Taiwan in 1998, 78 patients died with severe illnesses,
including AFP, aseptic meningitis, encephalitis, pulmo-
nary edema or hemorrhage, and myocarditis, among
whom around 80% had pulmonary edema or hemorrhage
(54). During an HFMD outbreak in Australia in 1999,
there was a study showing that 14 children with EV71
infection had neurological complications including men-
ingitis, acute cerebellar ataxia, acute transverse myelitis,
GuillainBarre´ syndrome, benign intracranial hyperten-
sion, febrile convulsion, and opso-myoclonus syndrome
(68). In a follow-up study of 142 children after EV71
infection with CNS involvement, neurological disease and
cardiorespiratory failure were likely associated with neu-
rologic sequelae (limb weakness and atrophy), delayed
neurodevelopment, and reduced cognitive function (69).
In 2012, more than 50 children, who presented with fever,
respiratory illness, and neurological complications, died
within a short period of time after admission to hospital
in Cambodia, where EV71 was eventually identified as a
possible cause of the outbreak (70).
Detection of EV71
Traditional methods of EV71 detection are virus isolation
and serological tests (40, 41, 45, 46, 48, 64, 71, 72). For cell
culture, human rhabdomyosarcoma (RD) and monkey
kidney cell lines (e.g., Vero) are commonly used to isolate
EV71 (1), but this method is rather time-consuming (take
days to weeks) and has poor sensitivity (73). For serology,
cases were reported as positive when paired sera from
patients showed fourfold increase in neutralizing anti-
body titers against EV71 (40, 4446, 48). However, acute
and convalescent sera are usually taken at least 2 weeks
apart (74), rendering serological tests on paired sera,
together with virus isolation, unsuitable for managing
EV71 in outbreak situations, during which early detec-
tion of EV71 is required to allow prompt implementation
of preventive and control measures. Since the late 1990s,
rapid and sensitive molecular diagnostic tests such as
reverse-transcriptase polymerase chain reaction (RT-
PCR) have been increasingly applied for EV71 detection.
In epidemiological studies during the HFMD outbreaks,
5?UTR and VP1 were the most widely used targets for
EV71 detection (Table 2). 5?UTR was used because this
region showed high sensitivity for the detection of EV71
(61, 73, 75). However, 5?UTR is a hot spot of recombina-
tion in enteroviruses (76, 77), making this region inap-
propriate for genotyping (21). In contrast, VP1 gene is
most commonly used for phylogenetic analysis as it
shows a high degree of genetic diversity and no homo-
logous recombination has been reported to take place
within the VP1 gene in EV71 (78). To better determine
the prevalence of EV71 in clinical specimens, 5?UTR
should be used for detection and VP1 for genotype and
subgenotype classification.
Genotypic changes in EV71
Based on molecular characterization using VP1 gene
sequences, EV71 was classified into genotypes A, B, and
C (Fig. 1) (79). The prototype strain BrCr isolated in
1970 during the epidemic in California was classified
as genotype A (40, 79, 80). There was no report on the
circulation of EV71 genotype A strains thereafter until
2008 when re-emergence of this genotype occurred in
central China (81). Genotype A might not be the first
genotype detected in human population because a novel
subgenotype of EV71 circulating in the Netherlands
during 19631967 was recently identified as subgenotype
B0 (23), which existed earlier than genotype A. Since the
1970s, EV71 strains of genotype B (subgenotypes B1B5)
have been circulating globally. Subgenotype B1 was the
major type responsible for EV71 epidemics in America
(79), Europe (6, 23, 82), Asia (21, 8385) and Australia
(23, 79) in the 1970s, while subgenotype B2 became
predominant in the United States (79), the Netherlands
(23), Australia (86), and Japan (83) in the 1980s. In the
mid-1980s, EV71 strains of subgenotype C1 emerged and
have been circulating in different regions afterwards
(Table 3) (4, 9, 10, 21, 23, 39, 5760, 79, 8292).
The emergence of a novel genotype or subgenotype
of EV71 can lead to large outbreaks, with well-known
examples in the Asia-Pacific region since 1997 (Table 3).
In Malaysia, a widespread community HFMD outbreak
with fatal cases occurred in 1997, during which the most
prevalent subgenotype B3 was co-circulating with other
subgenotypes B4, C1, and C2 (6, 21, 23, 53, 79, 85, 91).
Subgenotypes B4 and C1 were identified as a cause of an
outbreak in 2000 (6, 91), while subgenotype B5 was noted
in an outbreak in 2005 (65, 66, 85, 91). In Australia, co-
circulation of subgenotypes B3 and C2 contributed to a
large outbreak in 1999, with subgenotypic changes to
B4 and C1 in 2000 (4, 21, 23, 85, 86). In Singapore, three
major outbreaks have been caused by subgenotypes B4
(2000) and B5 (2006 and 2008) (4, 85, 93, 94). Brunei
reported its first EV71 outbreak in 2006, of which most
EV71 isolates belonged to subgenotype B5 (95). In
Taiwan, the predominant subgenotype C2 accounted
for a devastating EV71 outbreak in 1998, followed by a
shift to subgenotype B4 (19992003), C4 (20042005), C5
(2006), B5 (20072009), and C4 (2010) (8, 2123, 85,
96103). Intriguingly, similar pattern of inter-genotypic
change (a change from one genotype to another) of EV71
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Table 2. Summary of studies on the phylogeny of EV71 strains
Gene or region
Number of
nucleotides sequenced
Number of new strains for phylogenetic analysis
(country/collection date) References
5?UTR 440 13 (Malaysia/1997) AbuBakar et al. (75)
VP1 891 113 (USA, Australia, Colombia, the Republic of China,
Canada, Malaysia/19701998)
Brown et al. (79)
VP4/VP2 420 29 (Malaysia, Japan/1997; Taiwan/1998; Bulgaria,
Hungary, Japan, Taiwan, USA/19731980)
Shimizu et al. (151)
5?UTR 681 36 (Taiwan/1998) Wang et al. (61)
VP1 529633 16 (Taiwan/1998) Shih et al. (97)
VP1 341 20 (Japan, Malaysia, Singapore/19971998) Singh et al. (150)
VP4 207 3 (Taiwan/1986); 20 (Taiwan/1998) Chu et al. (98)
VP1 891 24 (Malaysia/19971998, 2000); 19 (Singapore/1998,
20002001);
23 (Australia/19992000)
McMinn et al. (4)
5?UTR and VP1 648 and 841 48 (Taiwan/19982000) for 5?UTR; 33 (Taiwan/19982000)
for VP1
Wang et al. (8)
5?UTR, VP4 and VP1 646, 207 and 855 1 (India/2001) Deshpande et al. (114)
VP4 and VP1 207 and 891 55 (USA, Malaysia, Singapore, Australia, Korea/
19722002) for VP4; 12 (Korea/2000; Malaysia/2002)
for VP1
Cardosa et al. (21)
VP1 891 11 (Korea/2000) Jee et al. (106)
VP1 891 43 (Malaysia/19972000) Herrero et al. (6)
VP1 891 5 (China/1997, 2000); 1 (Thailand/2002) Shimizu et al. (84)
VP4 and VP1 207 and 891 17 for VP4 and 19 for VP1 (China-Shenzhen/20012004) Li et al. (5)
VP1 891 1 (Brazil/1999) Castro et al. (113)
VP1 891 45 (Japan-Yamagata/19982003) Mizuta et al. (65)
VP4 207 121 (Japan-Fukushima/19832003) Hosoya et al. (83)
VP4 207 41 (Taiwan/1986, 19992005) Lin et al. (85)
VP1 891 48 (Australia-Sydney/19832001) Sanders et al. (86)
VP1 414 85 (Taiwan/19982005) Kung et al. (101)
VP4 and VP1 207 and 840891 7 for VP4 and 14 for VP1 (Malaysia-Sarawak/2000, 2003) Ooi et al. (66)
VP1 partial-891 1 with complete genome; others with partial VP1
(data not shown) (Norway/20022003)
Witsø et al. (57)
VP1 891 23 (Vietnam/2005) Tu et al. (10)
VP1 and 3Dpol 891 and 1391 32 (the United Kingdom/19982006) Bible et al. (88)
VP1 403 11 (Taiwan/20062007) Huang et al. (22)
5?UTR and VP1 723 and 891 16 (Austria/20012004) Ortner et al. (89)
VP1 891 199 (The Netherlands/19632008) van der Sanden et al. (23)
VP1 891 26 (Japan-Toyama/1983, 1989, 1994, 1997, 2000, 2003,
2006)
Iwai et al. (87)
VP1 891 31 (Japan-Yamagata/19902007) Mizuta et al. (104)
VP1 372 28 (Germany/19972007) Diedrich et al. (58)
VP1 837891 34 (Brunei/2006); 7 (Malaysia/2006) AbuBakar et al. (95)
VP1 891 56 (China-Shandong/2007) Zhang et al. (110)
VP1 891 3 (France/20072008) Vallet et al. (105)
VP1 255 6 (Hungary/2000, 20042005) Kapusinszky et al. (82)
VP1 436458 3 (Korea/2003) Jeong et al. (107)
VP1 403 11 (Taiwan/2008) Huang et al. (100)
VP1 891 5 (China-Lu’an/2008) Yu et al. (81)
VP1 891 10 (Singapore/2008) Wu et al. (93)
VP1 158159 23 (Thailand/20082009) Chatproedprai et al. (9)
VP1 891 28 (China-Jiangsu/2009) Mao et al. (112)
VP1 891 58 (France/1994, 19992000, 20032009) Schuffenecker et al. (60)
Cyril C. Y. Yip et al.
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has been observed in Japan in outbreaks since 1997
(65, 8385, 87, 104).
Inter-genotypic change of EV71 has also been detected
in Europe. In the Netherlands, genotype B (subgenotypes
B0, B1, and B2) from 1963 to 1986 was changed to
genotype C (subgenotypes C1 and C2) since 1987 (23).
In Denmark, only subgenotype C2 was identified in
20052006, with a shift to predominant subgenotype
B5 in 2007 (59). In Germany, a shift from subgenotype
B2 (19971998) to subgenotype C1 (20002003) has been
noted, followed by intra-genotypic change (a change
from one subgenotype to another of the same genotype)
to C4 (2004) and C2 (20062007) (58). Intra-genotypic
change of EV71 has been found in some other European
and Asian countries. Two studies demonstrated that there
was a shift from subgenotype C1 (20012003 in Austria;
Table 2 (Continued)
Gene or region
Number of
nucleotides sequenced
Number of new strains for phylogenetic analysis
(country/collection date) References
VP1 891 31 (China/2003, 20082009) Tan et al. (17)
VP2 159 29 (Denmark/20052008) Badran SA et al. (59)
VP1 NA 44 (Taiwan/2008) Lee et al. (99)
VP1 891 17 (China-Guangdong/2008) Sun et al. (12)
VP1 403891 6 (Thailand/20082009, 2011) Puenpa et al. (92)
VP1 891 20 (China-Henan/2009) Zhang et al. (111)
VP1 891 8 (China-Shanghai/2009) Yan et al. (14)
VP1 304 17 (China/2009) Yang et al. (13)
VP1 315706 6 (Greece/20092010) Siafakas et al. (109)
VP1 891 4 (ChinaNanchang/2010) Liu et al. (15)
VP1 NA 78 (China-Ningbo/20082011) Ni et al. (16)
NA: not available.
Fig. 1. Phylogenetic tree of the VP1 region of EV71 strains detected in various countries, showing different genotypes and subgenotypes
of EV71. Eight hundred and fifty-five nucleotide positions in each VP1 region were included in the analysis. The tree was constructed by
the neighbor joining method and bootstrap values calculated from 1,000 trees. The scale bar indicates the estimated number of
substitutions per 100 nucleotides. EV71 strains of potential novel genotype or subgenotype were highlighted in gray. GenBank
accession numbers are indicated in parentheses.
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Table 3. Summary of EV71 subgenotypes in different geographical regions from 1963 to 2011
Subgenotypes
Year A B0 (proposed) B1 B2 B3 B4 B5 C1 C2 C3
C4 (proposed
genotype D) C5
1963 NL
1965 NL
1966 NL
1967 NL
1970 USA JPN
1971 NL
1972 NL, USA
1973 JPN, NL, TW JPN
1974 AUS, NL AUS
1975 BUL, NL
1976 NL, USA
1977 USA NL
1978 HUN, NL, USA,
JPN
1979 NL, USA
1980 TW, USA
1981 NL, USA
1982 JPN NL, USA
1983 JPN, USA AUS, JPN, NL,
USA
1984 JPN
1985 JPN NL
1986 TW, USA NL, USA AUS
1987 USA USA AUS, NL, USA
1988 USA HK, USA
1989 JPN AUS, JPN, USA
1990 JPN AUS, JPN, NL,
USA
1991 AUS, CAN, NL,
USA
1992 AUS, NL, USA
1993 JPN JPN JPN, USA
1994 AUS, FRA, HK,
NL, USA
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Table 3 (Continued)
Subgenotypes
Year A B0 (proposed) B1 B2 B3 B4 B5 C1 C2 C3
C4 (proposed
genotype D) C5
1995 AUS, NL, USA AUS
1996 JPN AUS, JPN CHN, UK
1997 GER JPN, MAL, SIN JPN, MAL, SIN NL, MAL, USA JPN, HK, NL,
MAL, UK, USA
JPN
1998 GER SIN TW MAL, SIN, UK AUS, JPN, TW,
UK, USA
CHN, HK, TW
1999 AUS, HK, SIN MAL, TW FRA, HK, MAL,
UK
AUS, JPN,
FRA, NL, UK
HK
2000 AUS, JPN,
MAL, SIN, TW
SIN AUS, FRA,
GER, HK, HUN,
MAL, UK
FRA, JPN, NL KOR CHN, HK
2001 AUS, HK, SIN,
TW
AUT, GER, NL,
TUR, UK
FRA, JPN CHN, HK, TW
2002 JPN, MAL, SIN,
TW
AUT, HK, MAL,
NL, NOR, SIN,
THA, UK
HK, JPN, NL CHN, JPN
2003 JPN, MAL, TW JPN,MAL AUT, FRA,
GER, JPN,
MAL, NOR
CHN CHN, HK, JPN,
KOR
2004 FRA, NL, UK NL AUT, CHN,
FRA, GER,
JPN, HK, HUN,
TW
2005 MAL FRA, IRAN, NL,
MAL, UK, VNM
CHN,
DEN,
NL
CHN, HUN, HK,
TW, VNM
VNM
2006 BRU BRU,
MAL, SIN
FRA, UK CHN, DEN,
FRA, GER, UK
CHN, HK, JPN,
THA
TW
2007 DEN, TW DEN, NL CHN, DEN,
FRA, GER, HK,
NL, THA
CHN, HK, JPN TW
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2000 in Hungary) to C4 (2004 in Austria; 20042005 in
Hungary) (82, 89). During 20002009, all EV71 strains
belonged to genotype C in France, in which C1 strains
predominated from 2000 to 2005, but C2 strains became
predominant since 2007 (60, 105). In Korea, subgenotype
C3 was identified in an EV71 epidemic in 2000, followed
by the detection of subgenotype C4 in 2003 and 2009
(21, 85, 106108).
Circulation of a single EV71 subgenotype was reported
in several places. In Iran, only EV71 of subgenotype
C1 was detected from a child with AFP in 2005 (90).
In Greece, all EV71 strains detected from children with
HFMD, febrile illness, or maculopapular rash belonged
to subgenotype C2 in 20092010 (109). Coexistence of
more than one subgenotype was observed in some other
regions (Table 3). During 19982006, subgenotype C1
predominated in the United Kingdom, with the existence
of subgenotype C2 in 1999 and 2006 (88). The first report
of subgenotype C5 in Vietnam showed that this pre-
dominant subgenotype was co-circulating with subgeno-
types C1 and C4 in 2005 (10). In Thailand, subgenotypes
C1 and C4 were identified in 2008, followed by the
detection of subgenotypes C1, C2, C4, and B5 in 2009
(9, 84, 92, 110). In China, the major subgenotype C4,
which was further divided into C4a (20022011) and C4b
(19982004), co-circulated with subgenotype C2 (5, 12
17, 84, 110112). Similar subgenotype predominance was
noted in Hong Kong (situated on China’s south coast),
where the main subgenotype of EV71 belonged to C4,
with co-detection of a minority of subgenotypes B3, B4,
B5, C1, and C2 strains during 19982008 (39).
Identification of EV71 genotype or subgenotype has
not been standardized yet, although several studies have
proposed certain criteria for typing. Distinct clusters with
high bootstrap supports in phylogenetic trees constructed
by using VP1 gene indicated the presence of a novel
genotype or subgenotype of EV71 (4, 79). Furthermore,
cutoff values for genotyping and subgenotyping of
EV71 using VP1 have been proposed, with a nucleotide
sequence divergence of 1520% between genotypes and of
414% between subgenotypes (25, 79, 101). According
to these criteria, previously untyped EV71 isolates may
belong to a novel genotype or subgenotype. Two studies
demonstrated that an EV71 strain 6658-COL-94 from
Columbia and a strain 73442-PA-99 from Brazil were
closely related to genotype B isolates (79, 113). Based on
phylogenetic analysis using VP1 nucleotide sequences of
EV71 (Fig. 1), the two strains formed branches separate
from other genotype B strains. Moreover, VP1 sequence
divergence between the Colombian strain and other geno-
type B strains was 6.112% and between the Brazilian
strain and other genotype B strains was 8.212%, sug-
gesting that they should belong to novel subgenotypes
B6 and B7, respectively. As shown in Fig. 1, EV71 strains
2008-00643 and 2008-07776 from Taiwan (100) formedT
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a cluster distinct from subgenotype C2 isolates. In addi-
tion, the VP1 sequence divergence between theses Taiwanese
strains and other genotype C strains is 6.713.6%. These
indicated that the two Taiwanese strains should be
regarded as a new subgenotype C6. Phylogenetic analysis
of 5?UTR, VP4 and VP1 sequences of an EV71 strain
R13223-IND-01 isolated from a case of AFP in India in
2001 showed that it may belong to a novel genotype
(114). As shown in Fig. 1, this isolate formed a branch
distinct from other EV71 strains. Furthermore, the VP1
sequence divergence between this Indian strain and other
strains of EV71 genotypes A, B, and C was 14.918.5%.
These revealed that the strain R13223-IND-01 should be
designated as a new genotype E. Recently, Chan et al.
proposed new cutoff values for genotyping based on
complete genome sequences of EV71, with a nucleotide
divergence of 1722% between genotypes and of 1014%
between subgenotypes (25). Complete genome sequen-
cing and further sequence analysis are required to better
determine the genotype or subgenotype of EV71.
Relationship between EV71 genotypes and disease
severity
Several research groups have examined the relationship
between EV71 genotypes and outcomes of EV71 infec-
tions. In a study from Australia, EV71 of subgenotype C2
was strongly linked to severe neurological disease in 1999
(4). Another study from Malaysia revealed that children
infected with EV71 of subgenotype B4 were less likely to
have CNS complications than those infected with other
subgenotypes (66). However, a recent study from the
Netherlands demonstrated that children with genotype B
virus were more likely to have neurological complica-
tions than those with genotype C virus (23). In Taiwan,
EV71 of genotypes B and C could be isolated from both
fatal and mild HFMD cases from 1998 to 2000 (8, 97).
Furthermore, VP1 sequences of EV71 isolated from
patients with mild HFMD and fatal encephalitis in
Malaysia in 1997 were almost identical (79). Hence,
more careful and systematic analysis will be required to
delineate the correlation between the EV71 genotypes
and disease severity.
Recombination events in EV71
Under selective pressures from hosts and environment,
recombination possibly takes place when at least two
viruses infect the same cell, resulting in the production of
progenies with new genomic combinations that may favor
viral survival during evolution (115). As recombination in
RNA viruses might enhance their host range (116) and
pathogenicity (117), and confer antiviral resistance (118),
it is important to assess the impact of recombination
in EV71. Recombination is a common phenomenon in
human enteroviruses, with preferential recombination
sites in non-structural protein coding regions P2 and
P3 (Fig. 2), where a high nucleotide sequence identity
between two parental strains may favor homologous
recombination by a ‘copy-choice’ mechanism (34, 35).
Breakpoints are frequently detected at 5?UTR, P2 and P3
by recombination analysis using sequencing of different
gene regions or complete genomes (24, 37, 38, 76, 77,
119123). In a recent study using VP1 and 3D for
recombination analysis on 308 EV71 isolates collected
from 19 countries over a 40-year period, 11 3D clades
were identified, each specific to EV71 and associated with
specific subgenotypes but interspersed phylogenetically
with clades of CVA16 and other HEV-A serotypes (124).
Sporadic recombination events were detected within
genotypes but no evidence for inter-typic recombination
as described in other studies (24, 36, 37, 125). Since
recombination breakpoints can occur at 5?UTR and
different gene regions of EV71, amplification of two
gene regions (VP1 and 3D) may not be sufficient to reveal
the actual recombination events.
Fig. 2. Schematic diagram showing intra- and inter-typic recombination events occurred in EV71 strains SZ/HK08-5 and SZ/HK08-6
of subgenotype C4 (proposed genotype D).
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Recent studies on EV71 recombination usually involve
complete genome sequence analysis. During the HFMD
outbreaks in Malaysia in 1997, EV71 subgenotype B3
was predominant, which was also found in other areas
in the Asia-Pacific region including Japan, Singapore,
Australia, and Hong Kong (4, 21, 23, 36, 39, 83, 85) (Table 3)
but disappeared after 1999. Complete genome analysis
of two strains SHA63 and SHA66 showed that they were
most closely related to EV71 genotype B strains for
5?UTR, P1 and P2 regions, but to CVA16 for the P3 and
3?UTR (36). This was the first to demonstrate inter-typic
recombination (between different types of human enter-
oviruses, e.g., EV71 and CVA16). Since 1998, emergence
of EV71 subgenotype C4 has been responsible for the
HFMD outbreaks in China. Phylogenetic and bootscan
analyses on two complete genomes of EV71 C4 strains
SHZH98 and SHZH03 from Shenzhen revealed that they
were most closely related to EV71 subgenotype C2 strain
for P1 region, but to CVA16 for P3 region (37). In the
same study, a CVA16 strain Tainan5079 was closely rela-
ted to CVA16 strain G-10 for P1 region, but to EV71
strain BrCr of genotype A for P2 and P3 regions. These
indicated that inter-typic recombination events have
occurred between EV71 subgenotype C2 and CVA16
strain G-10, and between CVA16 strain G-10 and EV71
genotype A, both with a breakpoint at 2A region, a
recombination hot spot in enteroviruses (1, 120, 121).
Various recombinant forms of EV71 accounted for
outbreaks in Taiwan since 1998. Inter-typic recombina-
tion between EV71 and coxsackievirus A8 (CVA8) was
detected in EV71 subgenotype C2 isolates that were
responsible for the large outbreak associated with severe
encephalitis in 1998 (96), which was in line with a
previous study (126). During 20002001, outbreaks in
Taiwan were caused by EV71 subgenotype B4, which was
possibly evolved from genotypes B3 and B2 (96). From
2004 to 2005, the predominant EV71 subgenotype C4
emerged and was shown to be a recombinant resulting
from intra-typic recombination (between the same type of
human EV, e.g., EV71) between genotype C and genotype
B (96), consistent with a previous study (38).
In China, a dramatic increase in the number of HFMD
cases from 2007 to 2008 suggested EV71 and CVA16
might have undergone recombination (24). Complete
genome analysis of two EV71 strains (SZ/HK08-5 and
SZ/HK08-6) and two CVA16 strains (SZ/HK08-3 and
SZ/HK08-7) from Shenzhen revealed inter-typic recom-
bination between CVA16 strain G-10 and EV71 genotype
A at the 2A2B junction the two CVA16 strains (24), in
line with previous results on CVA16 strain Tainan5079
(37). For the two EV71 strains, intra-typic recombination
between EV71 genotypes C and B at 2A2B junction and
inter-typic recombination between EV71 genotype B and
CVA16 strain G-10 in 3C region were observed (Fig. 2).
These ‘double-recombinant’ EV71 strains circulating in
China and other EV71 subgenotype C4 strains were
proposed to be a novel genotype D (24). The proposal of
this new genotype was also supported by another study
conducted by Chan et al. (25). In this study, EV71
subgenotype C4 was shown to have a nucleotide sequence
divergence of 18.1% (1720%), which exceeded the
average threshold divergence of 14.95% for EV71 sub-
genotyping when comparing with EV71 subgenotypes
C1C5. Based on the evidence from the two studies
(24, 25), EV71 subgenotype C4 should be redesignated
as the novel genotype D. Since 2008, there has been an
increase in the number of studies on recombination in
EV71 during HFMD outbreaks in China, including the
‘double-recombinant’ subgenotype C4 strains probably
belonging to the proposed genotype D (11, 125, 127).
Although the correlation between natural recombination
in EV71 and pathogenicity remains uncertain, an in vitro
study demonstrated that a chimeric recombinant virus
with improved growth and larger plaque phenotypes
could be artificially constructed by replacing the struc-
tural region of a slow-growth EV71 strain with the region
of a rapid-growth EV71 strain (128). Thus, it is possible
to generate a highly pathogenic EV71 strain when a less
virulent strain can acquire an antigenically distinct capsid
region or non-structural regions from a more virulent
strain via natural recombination.
Over the past decade, EV71 of predominant subgeno-
type C4 has been co-circulating with some other subgeno-
types in mainland China and Hong Kong (5, 17, 23,
39, 129), which may increase the chance of recombination.
In addition, densely populated areas with poor hygiene,
sanitation, and healthcare infrastructure may further
hasten not only recombination, but also viral mutation.
As Hong Kong is a gateway to China with extensive
passenger movements and global transport networks, it
may be a place for the spread of novel EV71 mutants or
recombinants to other cities, posing pandemic threats as
in the case of SARS.
Antiviral strategies against EV71
Despite the occurrence of recurrent EV71 outbreaks with
severe complications and fatal cases in the past few
decades, effective antivirals against EV71 are still not
available (130). Intravenous immunoglobulin (IVIG) has
been used in patients with complicated EV71 infections,
which may help suppress viral replication and limit
organ damage through anti-inflammatory activities (66).
In vitro and in vivo studies demonstrated that ribavirin
and type I interferons exhibited protective effects on
EV71 (131, 132). Pleconaril has demonstrated antiviral
activity against a broad spectrum of EV serotypes in vitro
and in vivo (133), but it cannot inhibit the cytopathic
effect induced by EV71 (134). In a study by Shih et al.,
mutation in VP1 of EV71 was shown to confer resistance
to the inhibitory effects of pyridyl imidazolidinone (135).
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EV71 mutants resistant to inhibitors of 2C protein of
EV71, including metrifudil, N(6)-benzyladenosine and
NF449, have also been identified (136). In another study,
Chen et al. demonstrated that EV71 displayed resistance
to an antiviral agent DTriP-22 after an arginine-to-lysine
substitution (R163K) in 3D polymerase (137). So far,
none of these antivirals possessed efficacy high enough
for clinical use.
Due to the high frequency of mutations and recombi-
nation in EV71, viral factors may not be suitable targets
for drug design. In contrast, targeting cellular factors
temporarily dispensable for the host but essential for viral
replication may prevent viral escape. RNA interference
(RNAi) screening has been increasingly used to search
for cellular factors required for viral infections (138147)
and this strategy holds a potential for antiviral develop-
ment (148). Further investigations to identify host factors
important for EV71 replication will help explore the
mechanisms of EV71 pathogenesis.
Concluding remarks
Over the past few decades, EV71 epidemics have occurred
in various countries and caused a significant proportion
of severe complications and deaths in children, particu-
larly in the Asia-Pacific region. Mutation and recom-
bination are the major evolutionary forces leading to
emergence of genetically diverse EV71 variants that have
accounted for the recurrent HFMD outbreaks. Despite
recent findings of intra-typic and inter-typic recombina-
tion, the correlation between recombination and virulence
in EV71 remains unclear. Owing to the common occur-
rence of recombination in EV71, sequencing of more than
one region (e.g., VP1 and 3D) would allow the rapid and
accurate genotyping of EV71 in clinical settings. To date,
the majority of HFMD cases due to EV71 have been
noted in China, which is the most populous country in the
world. Since Hong Kong is well connected to China with
international travel networks, the former may be a hub
that facilitates the global dissemination of novel mutants
or recombinants of EV71, posing pandemic threats in the
near future. Continuous genomic studies on the evolution
of EV71 in Hong Kong and other Asia-Pacific regions are
important to detect new mutants or recombinants with
epidemic potential. Frequent genetic variations in EV71
have hampered the development of drugs targeting to viral
proteins and this obstacle could theoretically be overcome
by targeting host factors that are inessential for humans
but important for virus propagation. Genome-wide RNAi
screening technology has successfully been applied for the
identification of cellular factors crucial for replication
of emerging viruses, such as HIV and influenza viruses.
We foresee that this screening strategy will help unravel
EV71host interactions and provide insight into the
discovery of novel antivirals to combat future EV71
epidemics.
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